Roivant Sciences Analyst Price Targets - Benzinga

Roivant Sciences Ltd

ROIVNASDAQ

Trade with Public

Trade with Public

$37.52

0.411.1%

마지막 업데이트: Oct 29, 4:00 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Roivant Sciences Analyst Price Targets - Benzinga

Roivant Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Roivant Sciences (ROIV).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

13Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$36Upside to Avg. PT-3.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$46→$56
Oct 12, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Sep 17, 2026	Stifel	Alex Thompson	Initiate	Buy	$51
Sep 9, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$50→$55
Sep 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$42→$46
Sep 8, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$41→$47
Sep 8, 2026	Jefferies	Dennis Ding	PT Raise	Buy	$42→$52
Aug 28, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$41
Aug 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$42→$46
Aug 7, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$36→$42
Aug 7, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$34→$41
May 26, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$30→$36
May 21, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$35→$42
May 21, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$38→$41
May 21, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$34
Apr 16, 2026	Piper Sandler	Yasmeen Rahimi	PT Raise	Overweight	$22→$40
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$33→$34
Feb 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$26→$35
Feb 10, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$26→$33
Feb 9, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$28→$30

Analyst Ratings News

PRO
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56

Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $56.

Benzinga Newsdesk

This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.

Avi Kapoor

PRO
Wolfe Research Downgrades Roivant Sciences to Peer Perform

Wolfe Research analyst Andy Chen downgrades Roivant Sciences (NASDAQ:ROIV) from Outperform to Peer Perform.

Benzinga Newsdesk

This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.

Avi Kapoor

PRO
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51

Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55

TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $50 to $55.

Benzinga Newsdesk